BioMedNewsBreaks

ThursdayNov 02, 2023 11:57 am

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD), Bourne Partners to Collaborate in Evaluating Future Monetization of Potential PRV

PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company focused on advancing treatments for neurologic disorders, is working with leading financial services firm Bourne Partners. Bourne Partners specializes in the pharma, pharma services and consumer health spaces. According to the announcement, the collaboration is an important step in PaxMedica's strategy to explore potential monetization of a Priority Review Voucher prior to filing the NDA for PAX-101 for the treatment of African Sleeping Sickness. Although PaxMedica has not yet been granted a PRV and there is no guarantee that one will be awarded, the company believes  PAX-101 qualifies for the PRV program because African Sleeping…

Continue Reading

ThursdayNov 02, 2023 10:39 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present Phase 2 Study Results for INM-755 at 12th Annual WCI

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, will be presenting an oral presentation at the 12th World Congress on Itch (“WCI”); the event is scheduled for Nov. 5–7, 2023, in Miami. According to the announcement, the oral presentation is based on an abstract describing the phase 2 clinical study of investigational drug INM-755 cannabinol cream for the treatment of symptoms in patients with rare genetic skin disease called epidermolysis bullosa ("EB"). InMed Pharmaceuticals senior vice president of Clinical and Regulatory Affairs Alexandra Mancini will be presenting. The…

Continue Reading

WednesdayNov 01, 2023 2:13 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) to Present at BIO-Europe 2023

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that Catherine Vaczy, its EVP, general counsel and chief strategy officer, will be providing an overview of the company’s gene therapies for cancer and diabetes at the upcoming BIO-Europe 2023 Conference taking place in Munich, Germany. Vaczy’s presentation is slated to begin at 4:45 p.m UTC on Tuesday, Nov. 7, 2023. Several members of Genprex’s executive leadership team will be in attendance at BIO-Europe 2023. Those interested in meeting Genprex management during the event should request a meeting through…

Continue Reading

TuesdayOct 31, 2023 2:10 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases Q3 2023 Financial Report, Reports Possible Adjustment of Facility Terms by EIB

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, is reporting on its financial results for the third quarter ended Sept. 30, 2023; the report also included key business updates. Financial numbers to note in the report include R&D expenses of $1.13 million compared to $1.19 million for the same quarter in 2022; marketing, general and administrative expenses for the quarter totaled $0.97 million compared to $0.96 million for the three months ended Sept. 30, 2022; total operating expenses for the quarter came in at…

Continue Reading

TuesdayOct 31, 2023 2:01 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Third Quarter 2023 Results Conference Call

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (“VECG”) platform for patient use at home, announced that it will hold a conference call on Tuesday, Nov. 14, 2023, at 4:30 p.m. Eastern Time to discuss its results for the third quarter ended Sept. 30, 2023. The company will also review recent announcements, ongoing initiatives and anticipated 2024 milestones. HeartBeam CEO and Founder Branislav Vajdic, PhD, President Robert Eno and CFO Richard Brounstein will host the call, followed by a question-and-answer period. Accompanying the conference call will be a presentation, which…

Continue Reading

TuesdayOct 31, 2023 12:06 pm

BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Acquires Research Assets to Accelerate PAX-101 NDA Submission

PaxMedica (NASDAQ: PXMD), a pioneering biopharmaceutical company specializing in cutting-edge treatments for neurological disorders, today announced the successful acquisition of certain suramin research assets from Rediscovery Life Sciences (“RLS”). The assets were previously dedicated to the study of suramin’s potential efficacy in treating acute kidney injury resulting from chronic kidney disease. According to the announcement, the newly acquired data from RLS will play a crucial role in bolstering PaxMedica’s ongoing efforts to support the submission for the approval of PAX-101, specifically for the treatment of African sleeping sickness caused by the Trypanosoma brucei rhodesiense parasite. “Acquiring the research assets from…

Continue Reading

MondayOct 30, 2023 12:20 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Reports on 1-for-17 Reverse Stock Split

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic drug therapies (“APT”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, has released information regarding its 1-for-17 reverse stock split. According to the announcement, as a result of the reverse stock split of PaxMedica’s common stock that became effective at 8:03 a.m. ET today, the company’s common stock will begin trading on a split-adjusted basis tomorrow, Oct. 31, 2023, when the market opens. The company noted that its common stock will continue to trade under the existing trading symbol PXMD.…

Continue Reading

MondayOct 30, 2023 11:31 am

BioMedNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) Announces Planned Launch of Its Highly Anticipated Wellness Beverage

Safety Shot (NASDAQ: SHOT) today announced the upcoming direct-to-consumer launch of Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. Beginning the first week of December 2023, the beverage will be available for retail purchase at www.DrinkSafetyShot.com and www.Amazon.com. In addition, the company plans to launch business-to-business sales of Safety Shot to distributors, retailers, restaurants and bars in the first quarter of 2024. “We’re very excited to launch Safety Shot through our multichannel strategy designed to dominate e-commerce, quickly win retail shelf space, and establish longstanding ties…

Continue Reading

MondayOct 30, 2023 10:41 am

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Participation at BIO-Europe Munich 2023

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products primarily for the treatment of autoimmune and infectious diseases, will be attending and participating in BIO-Europe, one of Europe’s premier pharmaceutical industry partnering events. The event is slated for Nov. 6­–8, 2023, in Munich, Germany. According to the announcement, Scinai will showcase both its CDMO services, marketed under the brand Scinai Bioservices, and its in-house nanosized VHH antibody-based therapeutics pipeline. In addition, management will be available to meet with potential partners and clients. Scinai offers a state-of-the-art manufacturing facility for biopharmaceutical…

Continue Reading

FridayOct 27, 2023 11:43 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Secures $5.2M in Private Placement and Preferred Investment Option Offerings

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company today announced that it has closed its offering for the issuance and sale of 3,012,049 pre-funded warrants and preferred investment options to purchase up to an aggregate of 3,012,049 common shares, at a purchase price of $0.83 per pre-funded and associated preferred investment option, in a private placement priced at-the-market under Nasdaq rules. Per a previously announced definitive agreement with respect to certain of its outstanding preferred investment options issued in November 2022 and exercisable for 3,272,733…

Continue Reading